Meeting
2020 ASCO Virtual Scientific Program
Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in MDS and AML patients: Phase Ib results.
Presenter
David Andrew Sallman, MD
Moffitt Cancer Center
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Oral Abstract Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies
Sub Track
Myelodysplastic Syndromes (MDS)
Clinical Trial Registration Number
NCT03248479
Citation
J Clin Oncol 38: 2020 (suppl; abstr 7507)
DOI
10.1200/JCO.2020.38.15_suppl.7507
Abstract #
7507
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2024 ASCO Annual Meeting
Preliminary safety and efficacy of oral azacitidine (Oral-AZA) in patients (pts) with low-/Intermediate (Int)-risk myelodysplastic syndromes (MDS): Phase 2 results from the ASTREON trial.
Speaker: Guillermo Garcia-Manero, MD
Videos & Slides
ASCO Media Events
Presentation of Abstract LBA7000, Tolerability and efficacy of BrECADD versus BEACOPP in advanced stage classical Hodgkin lymphoma: GHSG HD21, a randomized study.
Speaker: Peter Borchmann, MD
Videos & Slides
2023 ASCO Annual Meeting
Updated safety and efficacy results from the phase I study of either LBL-007 (an anti-LAG-3 antibody) in combination with toripalimab (an anti-PD-1 antibody) or LBL-007 in combination with toripalimab and axitinib in patients with advanced melanoma.
Speaker: Xue Bai, MD
Speaker: Panel Discussion